US equities |
SPCX $175.16 ▲+2.38% NVDA $242.38 ▲+1.45% MU $1,067.70 ▲+0.35% MRVL $291.22 ▲+7.36% AMD $651.18 ▲+3.08% SNDK $1,678.12 ▼-1.53% AVGO $376.43 ▲+3.84% TSLA $380.81 ▲+0.55%
FinancialContent

DexCom, Inc. - Common Stock (NQ:DXCM)

84.52 -2.38 (-2.74%)
Delayed Quote Updated: 10:50 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
From DexCom, Inc.
Via Business Wire
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup ↗
Via Chartmill
News headline image
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
From DexCom, Inc.
Via Business Wire
DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation ↗
Via Chartmill
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup ↗
Via Chartmill
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock ↗
Via Chartmill
News headline image
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗
Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth. 
Via MarketBeat
Topics Initial Public Offering
News headline image
2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
Via StockStory
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Appoints Glenn Boehnlein to Board of Directors
From DexCom, Inc.
Via Business Wire
News headline image
3 Quality Compounders with Impressive Fundamentals
A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits... 
Via StockStory
News headline image
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers. Patient mo... 
Via StockStory
Topics Artificial Intelligence
News headline image
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
News headline image
3 Reasons DXCM Has Explosive Upside Potential
Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% in... 
Via StockStory
Topics Stocks
News headline image
1 Healthcare Stock to Target This Week and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
1 Surging Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
1 Growth Stock to Stash and 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 S&P 500 Stock on Our Buy List and 2 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
5 Insightful Analyst Questions From DexCom’s Q2 Earnings Call
DexCom’s second quarter was marked by robust revenue growth and a significant margin expansion, with management attributing performance to strong global dema... 
Via StockStory
Topics Earnings
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
DexCom (DXCM) Q2 2026 Earnings Call Transcript ↗
Revenue hit $1.31 billion with strong international growth and margin expansion. 
Via The Motley Fool
Topics Earnings
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Why Is DexCom (DXCM) Stock Rocketing Higher Today
What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter res... 
Via StockStory
Topics Artificial Intelligence
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗
Via Chartmill
News headline image
DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth
Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >